Abstract. BACKGROUND: Recently, many study have shown that Helicobacter pylori infection is crucial in development of atrophic gastritis, which is closely associated with gastric cancer. We con ducted a long-term endoscopic prospective follow-up study to investigate the development of gastric cancer in H. pylori-positive and -negative patients. METHODS: 1603 patients who underwent endos -copy and were assessed as to the presence of H. pylori infection by histology, rapid urease test and serologic test between April 1990 and March 1993 were entered. We prospectively studied 1246 sub jects with and 280 subjects without H. pylori infection for a mean follow-up of 7.8 years (range 1-10.6 years). RESULTS: Gastric cancer of both the intestinal and diffuse type developed in 36 (2.9%) infected patients but in none of the uninfected patients during follow-up. There was an increased risk for gastric cancer in infected patients with severe gastric atrophy and corpus predominant gastritis and intestinal metaplasia. Gastric cancer was detected in 21 (4.7%) of the patients with non ulcer dyspepsia, in 10 (3.4%) of those with gastric ulcer and in 5 (2.2%) of those with gastric hyperplastic polyp, at en rollment. No gastric cancer was detected in duodenal ulcer patients. CONCLUSION: These results suggest that the development of both types of gastric cancer is caused by H. pylori-associated gastritis, and the risk for development of gastric cancer in H. pylori-negative subjects is extremely low. Subjects having H. pylori-positive gastric mucosa with severe atrophy and/or corpus gastritis may be at partic ularly high risk for gastric cancer.
Introduction
Since the discovery of Helicobacter pylori (H. pylori),1 the diagnosis and treatment of upper gastro intestinal disease has changed greatly. In 1991, three nested serological follow-up studies2-4 reported a higher risk for the development of gastric cancer in subjects serologically positive for H. pylori infection. The WHO/IARC consensus group5 stated in 1994 that there is sufficient epidemiological and histological6,7 evidence in humans to classify H. pylori as a Type-1 carcinogen. Although the majority of recent studies have associated H. pylori with gastric cancer, there have been some contrary reports. 8, 9 The infection rates in gastric cancer patients vary greatly between different reports. These variations may be attributable to differ ences in the methods for detecting H. pylori in addition to differences in the patients' populations. Most pro spective studies8, 9 have used internal controls 'nested' within cohorts from which blood samples were taken some years before the onset of clinical gastric cancer. False negative cases are not uncommon, however, with 
Patients and procedures
Between April 1990 and March 1993, 1603 con -secutive patients diagnosed as active duodenal ulcer (DU), active gastric ulcer (GU), gastric hyperplastic polyp (GP) and no findings (non ulcer dyspepsia: NUD) by endoscopy were enrolled in a prospective study. They were assessed for H. pylori status and followed-up endoscopically for early detection of gas tric cancer. Patients with severe underlying diseases including gastric cancer, adenoma or those with gastric resection and subjects who had continuously received non-steroidal anti-inflammatory drugs (NSAIDs) were excluded. Seventy seven patients who refused a second endoscopic examination were excluded. The remaining 1524 patients (869 males and 657 females; 20-76 years old, mean age 52 years old) were analyzed in the study. Endoscopies with biopsies were performed in all pa tients at enrollment and every 1 and 3 years. Follow-up was censored due to deaths from other causes and use of antibiotic treatment for H. pylori eradication. The mean duration of follow-up was 7.8 years (range 1-10.6 years). All patients gave written informed consent.
Endoscopy and Histological examination
All endoscopic examinations were performed with only local anesthesia (lidocaine). An Olympus video scope (model GIF-230) was used. Four biopsy speci mens were taken, 2 each from the greater curvature of the antrum and from the upper body of the stomach. Of these 4 specimens, 2 were fixed in formalin and assessed for H. pylori (Giemsa staining) and the degree of neu trophil infiltration and intestinal metaplasia (haema toxylin eosin staining). The remaining 2 were used for rapid urease test (CLO). The degree of neutrophil in filtration was classified into 4 grades (none: 0, mild: 1, moderate: 2, and marked: 3) and expressed as a score according to the Updated Sydney System.14 Consensus was reached through revision of all the slides by the pathologists, leading to final conclusive scores. Sub sequently, distribution pattern of active gastritis was classified into 4 types (no gastritis, antral predominant gastritis, and pangastritis and corpus predominant gas tritis). The degree of intestinal metaplasia was classi fied into 2 grades (absence or presence) because of the multifocal distribution of metaplasia may lead to selec tion bias in only two biopsy specimens. Since only two biopsy were taken, gastric mucosal atrophy was eval uated according to the endoscopic atrophy border scale patients in the study included only NUD. Atrophy and intestinal metaplasia of any grade was found in only 4% and 2% of the uninfected group at enrolment and only 2% had gastritis, all antral predominant. On the other hand, in the infected group moderate atrophy was found in 53%, and severe atrophy in 17%. Antral pre dominant gastritis was found in 56%, pangastritis in 27% and corpus predominant in 17%. 37% had intesti nal metaplasia. There were significant differences in these parameters between both groups (P<0.0001 by Chi-squared test). Duration of follow-up in infected group was significantly shorter than that in uninfected group (P=0.0008), because 253 of 1256 infected pa tients received eradication therapy at an early stage of follow-up.
The development of gastric cancer during follow-up in each group is shown in Table 1 . Gastric cancer of both the intestinal and diffuse type developed in 36 (2.9%) infected patients but in none of the uninfected patients during follow-up. Because no gastric cancer (16 males and 7 females; mean age 64y, 44-76y at baseline, 53-83, mean age 70y at the detec tion of gastric cancer) and 13 diffuse type (6 males and 7 females; mean age 52y, 41-68 y at baseline, 47-75, mean age 58y at the detection of gastric cancer). Patients' mean age at enrolment and at the time of de tection of gastric cancer was significantly younger in the diffuse type than the intestinal type (P<0.0001).
This prospective follow-up of a large series of pa tients aimed to detect early gastric cancer by endoscopy after evaluation of H. pylori infection using biopsy and serology. During the observation period, gastric cancer appeared only in patients with H. pylori infection and not in uninfected patients. The results of this study support a recent meta-analysis reported by Huang et al.,8 which showed that H. pylori infection was epi demiologically involved in the onset of gastric cancer. In Japan, it has been reported that 300,000 individuals or 0.5% of the 60 million who are H. pylori positive develop gastric cancer annually,'' which means that 5% of H. pylori positive individuals develop gastric cancer every 10 years. The results of the present study support this estimate and it is clear that the risk of gas tric cancer developing in H. pylori carriers is extremely high in Japan.
This study also shows that it is very rare for individ uals without H. pylori infection to develop gastric can cer. In many previous epidemiological studies showing a close relationship between H. pylori infection and gastric cancer, a large number of H. pylori serologically negative patients were found to have cancer.8 9 Recent studies10-11 have shown that false-negative results oc cur using the serum antibody method, so it is possible that the H. pylori positive rate has been underestimated in gastric cancer patients. Tabata et al.12 studied the H . pylori positive rate in gastric cancer patients using var ious methods and concluded that false-negative results occur with the serum antibody method. They also stated that a biopsy from the greater curvature of the upper gastric body should be taken because this results in fewer false negatives. Enomoto et al. 22 performed an immunohistological study taking biopsy specimens from the greater curvature of the upper gastric body and H . pylori antibodies, and found that the H. pylori positive rate was 98% in gastric cancer patients . Their results and our findings suggest that when H . pylori infection is carefully sought, there are very few H . pylori negative Table 2 The Baseline Abnormalities of the Gastric Mucosa in Both Groups gastric cancer patients. In H. pylori negative patients, it is rare to find histological gastritis, especially neu trophil infiltration, and it is well known that little gastric mucosal atrophy occurs .23, 24 The same results were obtained in this study. Thus, the onset of gastric cancer is based on histological gastritis or atrophic gastritis associated with H. pylori infection.
The increased risk for gastric cancer in infected patients
The background gastric mucosa at baseline in all infected patients and in the 36 gastric cancer patients is shown in Table 2 . Gastric cancer developed in 3 (0.8%) of 381 patients with no or mild atrophy, 18 (2.7%) of 657 with moderate atrophy and 15 (7.2%) of 208 with severe atrophy. Gastric cancer developed in 2 (0.3%) out of 699 patients who had antral predominant gastritis at the start of follow-up, 14 (4.2%) of 337 with pangas tritis and 20 (9.5%) of 210 with corpus predominant gastritis. Gastric cancer developed in 5 (0.6%) of 782 patients without intestinal metaplasia, 26 (5.6%) of 464 with intestinal metaplasia. An increased risk for gastric cancer in infected patients with moderate or severe at rophy (Relative Risk (RR) and 95% confidence inter val of the difference: CI with no or mild atrophy: 2.8 or 4.9, 1.5-5.2 or 2.8-19.2), and pangastritis or corpus predominant gastritis (RR, 95% CI with antral pre dominant pattern: 15.6 or 34.5, 6.5-36.8 or 7.1-166.7) and presence of intestinal metaplasia (RR, 95% CI with no intestinal metaplasia: 6.5, 2.6-16.1).
The frequency of severe atrophy, corpus predomi nant gastritis and presence of intestinal metaplasia was significantly higher in patients with intestinal type than in diffuse type gastric cancer (P=0.002,<0001 and =0.0083 by Fischer extract method). Notably, in 14 patients with diffuse type nine had moderate atrophy and 10 had pangastritis. The development of gastric cancer in various diseases in H. pylori-positive patients (Table 3) Gastric cancer was detected in 21 (4.7%) of the pa tients with NUD, in 10 (3.4%) of those with GU and in 5 (2.2%) of those with GP at baseline. No gastric cancer was detected in DU patients. The frequency of gastric cancer development in NUD, GU and GP patients was significantly higher than that in DU patients (P=0.0028, P=0.0106 and P=0.0448 by Fischer ex tract method). Notably, the frequency of diffuse type cancer in GU was significantly higher than that in NUD and GP (P=0.0315 by Chi-squared test) and the mean age (52.7y) of gastric cancer in GU was significantly younger than that in NUD (62.6 y) (P=0.0087 by t test). 
